Hormone Produced in Stomach Could Boost Resistance to Parkinson's

Researchers have discovered that a hormone produced in the stomach called ghrelin could be used to boost resistance to or even slow the development of Parkinson's disease.

Parkinson's disease is caused by a degeneration of dopamine neurons in an area of the midbrain known as the substantia nigra, which is responsible for dopamine production. Reduced production of dopamine in late-stage Parkinson's disease causes symptoms such as severe difficulty in walking, restricted movements, delays in moving, lack of appetite, difficulty eating, periods of remaining motionless (known as "freezing") and head and limb tremors.

Parkinson's disease can develop when the dopamine cells degenerate and die. The researchers found that ghrelin is protective of the dopamine neurons. "We also found that, in addition to its influence on appetite, ghrelin is responsible for direct activation of the brain's dopamine cells," said study author Tamas Horvath. "Because this hormone originates from the stomach, it is circulating normally in the body, so it could easily be used to boost resistance to Parkinson's disease or it could be used to slow the development of the disease."

Image: 3D representaion of dopamine.

The researchers conducted the study in mice that received ghrelin supplementation and in mice that were deficient in ghrelin hormone and in the ghrelin receptor. When compared to controls, mice with impaired ghrelin action in the brain had more loss of dopamine. Horvath said the results could be easily translated to human use because the ghrelin system is preserved through various species.

Ghrelin was previously associated with the release of growth hormones, appetite, learning, memory, and with the reward circuitry of the brain that regulates food cravings. Recent human studies show that body mass index, stored fat and diabetes are linked to Parkinson's disease. Past research also shows that obesity is a risk factor for neurodegeneration in mice.

The research team will in future studies try to determine ghrelin levels in both healthy individuals and Parkinson's disease patients. They will also determine whether altered ghrelin levels might be a biomarker of Parkinson's disease development and vulnerability.
References:
1. Tamas Horvat, et al. Ghrelin Promotes and Protects Nigrostriatal Dopamine Function via a UCP2-Dependent Mitochondrial Mechanism. J. Neurosci., Nov 2009; 29: 14057 - 14065 ; doi:10.1523/JNEUROSCI.3890-09.2009.
2. Image by Sbrools.

New Clues for Cause of Brain Cell Death in Parkinson's and Alzheimer's

Although their genetic underpinnings differ, Alzheimer's disease, Parkinson's disease and Huntington's disease are all characterized by the untimely death of brain

Neurons Destroyed by Combination of 3 Molecules in Parkinson's Disease

Researchers have revealed that three molecules are responsible for neuron death in Parkinson's disease, providing a better understanding of how to save the neurons. The three molecules:

Parkinson's Disease Study Provides Insight Into Behavioral Addictions

New research unravels the brain mechanisms that underlie the ability of a standard drug treatment for Parkinson's disease to elicit compulsive behaviors in some patients with the disease.

Parkinson's Disease Risk 5 Times Greater for Gaucher Disease Carriers

According to a study by an international research team, carriers of a rare, genetic condition called Gaucher disease have a 5 times greater risk of developing Parkinson's disease. Previous

Molecules Found to Protect Cells from Toxicity in Parkinson's Disease

Several structurally similar small molecules appear capable of protecting cells from alpha-synuclein toxicity in multiple models of Parkinson's disease, according to Whitehead Institute